PARP Inhibitor
-
Theophylline-platinum(IV) prodrug-1
0 ImagesCat. No.: HY-175257Theophylline-platinum(IV) prodrug-1 is a PARP-1 inhibitor. Theophylline-platinum(IV) prodrug-1 enhances DNA damage, ROS production, mitochondrial dysfunction, apoptosis and S-phase arrest, along with reducing invasion and metastasis in cells. Theophylline-platinum(IV) prodrug-1 exhibits superior antitumor activity in the xenograft SKOV3-BRCA1-KD tumor model. Theophylline-platinum(IV) prodrug-1 can be used for the study of ovarian cancer.
-
HYDAMTIQ
0 ImagesCat. No.: HY-155458CAS No.: 1201832-32-7HYDAMTIQ is a PARP-1/2 inhibitor (IC50: 29-38 nM) with anticancer, anti-inflammatory, and ischemic protective effects. HYDAMTIQ inhibits pulmonary PARP activity, is effective against allergen-induced cough and dyspnea, and inhibits bronchial hyperresponsiveness to methacholine. HYDAMTIQ has broad-spectrum tumor suppressor effects, including ovarian and breast cancers, prostate and pancreatic tumors, and glioblastoma multiforme. HYDAMTIQ has demonstrated in vivo efficacy in animal models of cerebral ischemia, asthma, cancer, and more.
-
Paris saponin VII (Standard)
0 ImagesCat. No.: HY-N3584RCAS No.: 68124-04-9Synonyms: Chonglou Saponin VII (Standard)Paris saponin VII (Standard) is the analytical standard of Paris saponin VII. This product is intended for research and analytical applications. Paris saponin VII (Chonglou Saponin VII) is a steroidal saponin isolated from the roots and rhizomes of Trillium tschonoskii. Paris saponin VII-induced apoptosis in K562/ADR cells is associated with Akt/MAPK and the inhibition of P-gp. Paris saponin VII attenuates mitochondrial membrane potential, increases the expression of apoptosis-related proteins, such as Bax and cytochrome c, and decreases the protein expression levels of Bcl-2, caspase-9, caspase-3, PARP-1, and p-Akt. Paris saponin VII induces a robust autophagy in K562/ADR cells and provides a biochemical basis in the treatment of leukemia.
-
PARP1-IN-27
0 ImagesCat. No.: HY-161934PARP1-IN-27 (Compound 9B) is the inhibitor for PARP1 and PARP2, with IC50 of 2.53 nM and 6.45 nM in cell SUM149PT. PARP1-IN-27 inhibits the proliferation of BRCA-mutated cancer cells SUM149PT, HCC1937 and Capan-1, with IC50 of 0.62, 1.91 and 4.26 μM respectively. PARP1-IN-27 aggravates DNA double-strand breaks, increases ROS generation, arrests cell cycle at G2/M phase, and induces apoptosis in SUM149PT.
-
Ru3
0 ImagesCat. No.: HY-155348Ru3 is a poly(ADP-ribose) polymerase 1 inhibitor. Ru3 induces apoptosisin MCF-7 cells by multiple modes, inclusive of inducing DNA damage, suppressing DNA damage repair, disturbing cell cycle distribution, decreasing the mitochondrial membrane potential, and increasing the intracellular reactive oxygen species levels.
-
TNKS-IN-2
0 ImagesCat. No.: HY-117700CAS No.: 1584646-59-2TNKS-IN-2 (compound 40) is a potent and selective tankyrase (TNKS) inhibitor with pIC50 values of 8.1, 7.0 for TANKS and Wnt, respectively.
-
PARP1-IN-6
0 ImagesCat. No.: HY-139879CAS No.: 1654735-36-0PARP1-IN-6 is a dual tubulin/PARP-1 inhibitor with IC50 values of 0.94 and 0.48 μM, respectively.
-
Lotixparib
0 ImagesCat. No.: HY-177100CAS No.: 2640677-63-8Lotixparib (Example 1) is an inhibitor of poly(ADP-ribose)polymerase-1 (PARP-1). Lotixparib has cytoprotective effect against a retinal disease. Lotixparib can be studied in research for PARP-1-associated diseases.
-
2-Chlorohexadecanoic acid (Standard)
0 ImagesCat. No.: HY-131688RCAS No.: 19117-92-1Neomycin (sulfate) (Standard) is the analytical standard of Neomycin (sulfate). This product is intended for research and analytical applications. Neomycin sulfate, an aminoglycoside antibiotic, exerts antibacterial activity through irreversible binding of the nuclear 30S ribosomal subunit, thereby blocking bacterial protein synthesis. Neomycin sulfate is a known phospholipase C (PLC) inhibitor. Neomycin sulfate potently inhibits both nuclear translocation of angiogenin and angiogenin-induced cell proliferation and angiogenesis.
-
TMLB-C16
0 ImagesTMLB-C16 is a potent and orally active B3GAT3 inhibitor with a KD of 3.962 μM. TMLB-C16 suppresses proliferation and migration, and induces cell cycle arrest and apoptosis in MHCC-97H (IC50 = 6.53 μM) and HCCLM3 cells (IC50 = 6.22 μM). TMLB-C16 inhibits tumor growth in both MHCC-97H and HCCLM3 xenograft tumor mouse models without causing obvious toxicity. TMLB-C16 can be used for hepatocellular carcinoma research.
-
Sino-C
0 ImagesCat. No.: HY-179526Sino-C is a Sinomenine (HY-15122) derivative with anticancer activity. Sino-C broadly disrupts cholesterol homeostasis by upregulating key genes such as SREBF2 and HMGCS1, leading to intracellular cholesterol accumulation and lipid droplet formation. Sino-C-induced metabolic dysregulation further triggers lipid peroxidation and endoplasmic reticulum (ER) stress, initiating a unique form of hybrid cell death including apoptotic (cleaved PARP) and necrotic-like features. Sino-C thus serves as a useful compound for research in colorectal cancer, lung cancer and breast cancer.
-
Tiparp Mouse Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS14547Tiparp Mouse Pre-designed siRNA Set A contains three designed siRNAs for Tiparp gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
4,4′-Secalonic acid D
0 ImagesCat. No.: HY-N15380CAS No.: 2265910-52-74,4′-Secalonic acid D (Compound 12) is a PARP1 inhibitor. 4,4′-Secalonic acid D induces the accumulation of ROS and DNA damage, activates the caspase-3/GSDME pathway, and triggers apoptosis and pyroptosis of tumor cells by inhibiting PARP1. 4,4′-Secalonic acid D has anti-tumor activity.
-
Cimicifugic acid A
0 ImagesCat. No.: HY-N17665CAS No.: 205114-65-4Cimicifugic acid A is a cytotoxic caffeic acid derivative that can be isolated from the rhizomes of Cimicifuga heracleifolia. Cimicifugic acid A shows cytotoxic activity against cancer cells, and increases expression of cleaved PARP, thereby exhibiting pro-apoptotic activity. Cimicifugic acid A can be used for colon cancer research.
